Induced pluripotent stem cells (iPSC) shown to form multiple types of functional lymphocytes in vivoMarch 29, 2016
A new study demonstrates that iPSC have the potential to differentiate into multiple lineages of functional lymphocytes, including CD4+ T cells, B cells, and natural killer cells, without bias. The ability to generate truly functional lymphocytes from somatic cell-derived hematopoietic stem cells supports the clinical application of iPSC technology to develop treatments for hematological disorders, as concluded in the study published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until April 28, 2016.
Tianshu Lan and coauthors from Medical College of Xiamen University (Xiamen City) and Chinese Academy of Sciences (Beijing), China, provided a normal environment in which to compare the growth and differentiation capacity of hematopoietic cells derived from IPSC and from embryonic stem cells (ESC). The results show that lymphocytes generated from iPSC had the same capacity to proliferate and secrete chemical signals such as cytokines as did those from ESC when stimulated.
In the article "Induced Pluripotent Stem Cells Can Effectively Differentiate into Multiple Functional Lymphocyte Lineages In Vivo with Negligible Bias", the researchers further report that lymphocytes generated by iPSC-derived bone marrow cells could repopulate the hematopoietic systems of lethally irradiated recipient animals.
"This sort of side-by-side characterization and demonstration of the differential potential of iPSC and ESC is an absolute necessity to elevate what we do in stem cell research from conjecture and assumption to rigorous applicability and then clinical translation," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers . website.
Mary Ann Liebert, Inc./Genetic Engineering News
Related Lymphocytes Current Events and Lymphocytes News Articles
Two-pronged attack on chemotherapy-resistant leukemia cells
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer in Switzerland. Despite intensive chemotherapy, one fifth of the patients suffer a relapse, which usually goes hand in hand with a poor prognosis.
Endogenous retroviruses: Lethal reawakening
Retroviral DNAs integrate into host genomes, but their expression is normally repressed by cellular defense mechanisms.
What foods can help fight the risk of chronic inflammation?
A new study by the University of Liverpool's Institute of Ageing and Chronic Disease has identified food stuffs that can help prevent chronic inflammation that contributes to many leading causes of death.
Salt-inducible kinases may have therapeutic potential for autoimmune diseases
A new research report appearing in the May 2016 issue of the Journal of Leukocyte Biology, suggests that specific enzymes, called "salt-inducible kinases," may be able to help curb runaway inflammation associated with autoimmune diseases like Crohn's disease, arthritis, and psoriasis.
Autoimmune diseases gonna be defeated
An international team of scientists led by the Lomonosov Moscow State University group made a significant step in creating a new type of drug for treatment of autoimmune diseases, such as rheumatoid arthritis and Crohn's diseaase.
Adenosine deaminase may help the immune system fight HIV on its own
New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug.
Viral infection during pregnancy causes autism-like behaviors in mice
A study published in the journal Science found that activation in pregnant mice of a particular immune response, similar to what may occur with certain viral infections during pregnancy, alters the brain structure of the mouse offspring and causes behavioral changes, reminiscent of those observed in humans with autism spectrum disorder (ASD).
Novel RNA delivery system may treat incurable blood cancers
With a median survival rate of just five to seven years, Mantle Cell Lymphoma (MCL) is considered the most aggressive known blood cancer -- and available therapies are scarce.
Three studies point to effectiveness of new therapies for multiple myeloma
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.
Study shows ibrutinib superior to traditional chemotherapy in untreated chronic leukemia patients
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
More Lymphocytes Current Events and Lymphocytes News Articles